Dataset Information

TMIC-29. REPROGRAMMING BONE MARROW OF TUMOR-BEARING HOSTS FOR GLIOMA IMMUNOTHERAPY

ABSTRACT: Abstract INTRODUCTION We recently demonstrated that hematopoietic stem and progenitor cell (HSC) transfer during adoptive T cell immunotherapy (ACT) for malignant brain tumors facilitates extended survival and long-term cures. HSCs migrated to tumors and used T cell-released IFN-g to differentiate into dendritic cells (DCs). In those studies, we transferred syngeneic HSCs from naïve hosts that were not endemic to the tumor-bearing hosts, unlike the clinical paradigm of autologous transfers. In peripheral cancers, HSCs of tumor-bearing hosts (TB HSCs) possess considerable immunosuppressive potential. OBJECTIVE We therefore evaluated the immunologic function of HSCs from naïve and tumor-bearing hosts to determine if malignant gliomas affect the immune-potentiating function of HSCs. METHODS We used treatment-resistant intracranial gliomas KR158B and GL261 to generate TB HSCs that were isolated from the bone marrow. We then performed in vitro HSC culture experiments alone and with activated T cell supernatants to study HSC differentiation by flow cytometry. Intravenous transfers were used to study HSC differentiation in brain tumors as well as survival benefit during ACT. RESULTS Culturing naïve or TB HSCs led to differentiation into 30% or 60% myeloid-derived suppressor cells (MDSCs; CD11b+Ly-6G/6C+), respectively. However, when cultured in activated T cell supernatants containing IFN-g, both HSC types differentiated into 30% MDSCs and 80% MHCII+ antigen-presenting cells. We then determined that TB HSCs express more IFN-gR than naïve HSCs including 40% more IFN-gR1 and 90% more IFN-gR2 on DC progenitors. In vivo, ACT rescued intratumoral TB HSC differentiation, prolonged median survival, and led to long-term cures. CONCLUSIONS While gliomas exert an immunosuppressive pressure on TB HSCs, ACT can reprogram TB HSC differentiation into functional antigen-presenting cells. A phase I trial evaluating the impact of HSC transfer on adoptive immunotherapy in pediatric high-grade gliomas is underway at our center (ACTION; clinicaltrials.gov NCT03334305).

SUBMITTER: Wildes T

PROVIDER: S-EPMC6216412 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:Malignant gliomas manifest frequent tumor recurrence after surgical resection and/or other treatment because of their nature of invasiveness and dissemination. The recognized brain tumor-tracking property of neural progenitor/stem cells opened the possibility of targeting malignant brain tumors using neural progenitor/stem cells. We and others have previously shown that fetal neural progenitor/stem cells can be used to deliver therapeutic molecules to brain tumors. Our recent work has further shown that gene delivery by bone marrow-derived neural progenitor/stem cells achieves therapeutic effects in a glioma model. In this study, we isolate and characterize bone marrow-derived neural progenitor/stem cells, which also express the chemokine receptor chemokine CXC receptor 4 (CXCR4). We show that CXCR4 is required for their chemotaxis and extracellular matrix invasion against a gradient of glioma soluble factors. Furthermore, beta-galactosidase-labeled bone marrow-derived neural progenitor/stem cells implanted in the contralateral side of the brain were shown to track gliomas as early as day 1 and increased through days 3 and 7. Intracranial glioma tracking by bone marrow-derived neural progenitor/stem cells is significantly inhibited by preincubation of bone marrow-derived neural progenitor/stem cells with a blocking anti-CXCR4 antibody, suggesting a CXCR4-dependent tracking mechanism. Glioma tracking bone marrow-derived neural progenitor/stem cells were found to express progenitor/stem cell markers, as well as CXCR4. Although bromodeoxyuridine incorporation assays and proliferating antigen staining indicated that tumor tracking bone marrow-derived neural progenitor/stem cells were mostly nonproliferating, these cells survive in the local tumor environment with little apoptosis. Elucidating the molecular mechanism of brain tumor tracking by adult source stem cells may provide basis for the development of future targeted therapy for malignant brain tumors.

Project description:Reticuloendothelial macrophages engulf ?0.2 trillion senescent erythrocytes daily in a process called erythrophagocytosis (EP). This critical mechanism preserves systemic heme-iron homeostasis by regulating red blood cell (RBC) catabolism and iron recycling. Although extensive work has demonstrated the various effects on macrophage metabolic reprogramming by stimulation with proinflammatory cytokines, little is known about the impact of EP on the macrophage metabolome and proteome. Thus, we performed mass spectrometry-based metabolomics and proteomics analyses of mouse bone marrow-derived macrophages (BMDMs) before and after EP of IgG-coated RBCs. Further, metabolomics was performed on BMDMs incubated with free IgG to ensure that changes to macrophage metabolism were due to opsonized RBCs and not to free IgG binding. Uniformly labeled tracing experiments were conducted on BMDMs in the presence and absence of IgG-coated RBCs to assess the flux of glucose through the pentose phosphate pathway (PPP). In this study, we demonstrate that EP significantly alters amino acid and fatty acid metabolism, the Krebs cycle, OXPHOS, and arachidonate-linoleate metabolism. Increases in levels of amino acids, lipids and oxylipins, heme products, and RBC-derived proteins are noted in BMDMs following EP. Tracing experiments with U-13C6 glucose indicated a slower flux through glycolysis and enhanced PPP activation. Notably, we show that it is fueled by glucose derived from the macrophages themselves or from the extracellular media prior to EP, but not from opsonized RBCs. The PPP-derived NADPH can then fuel the oxidative burst, leading to the generation of reactive oxygen species necessary to promote digestion of phagocytosed RBC proteins via radical attack. Results were confirmed by redox proteomics experiments, demonstrating the oxidation of Cys152 and Cys94 of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and hemoglobin-?, respectively. Significant increases in early Krebs cycle and C5-branched dibasic acid metabolites (?-ketoglutarate and 2-hydroxyglutarate, respectively) indicate that EP promotes the dysregulation of mitochondrial metabolism. Lastly, EP stimulated aminolevulinic acid (ALA) synthase and arginase activity as indicated by significant accumulations of ALA and ornithine after IgG-mediated RBC ingestion. Importantly, EP-mediated metabolic reprogramming of BMDMs does not occur following exposure to IgG alone. In conclusion, we show that EP reprograms macrophage metabolism and modifies macrophage polarization.

Project description:BackgroundGlioma immunotherapy is an active area of clinical investigation. Glioma-associated immunosuppression remains an obstacle to efficacious immunotherapy, and combination approaches are likely necessary for durable success. OX40 is a member of the tumor necrosis factor receptor superfamily that is upregulated on activated lymphocytes, ligation of which results in enhanced activity and may be active against cancer. We sought to confirm the efficacy of agonist anti-OX40 immunotherapy against glioma and hypothesized that it is complementary with irradiated whole tumor cell vaccination.MethodsGL261 tumor cells were implanted into the right frontal lobes of syngeneic mice, which were then treated with controls, agonist anti-OX40 monoclonal antibody, vaccination with subcutaneous injection of irradiated granulocyte macrophage colony stimulating factor (GM-CSF)-expressing GL261 cells (GVAX), or vaccination + agonist anti-OX40 therapy. Animals were followed for survival. On day 18, splenocytes were harvested for enzyme-linked immunosorbent spot analyses and brains were harvested for immunohistochemistry and flow cytometry analyses of infiltrating lymphocytes.ResultsCombination immunotherapy with GVAX and systemic agonist anti-OX40 monoclonal antibody improved survival by 14 days over controls (median survival 36 vs 22 days, P < 0.00005). Systemically, T helper cell type 1 (Th1) antitumor immunity was enhanced significantly by combination therapy. In the brain, combination immunotherapy increased the percentage of Th1 CD4+ T lymphocytes and reduced the fraction that were Th2. In the brain, vaccination improved the ratio of CD8+ to FoxP3+ T lymphocytes, while combination immunotherapy reversed intracranial T-lymphocyte exhaustion, reducing their coexpression of programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) as well as PD-1 and lymphocyte-activation gene 3 (LAG-3).ConclusionsAnti-OX40 immunotherapy is active against intracranial glioma and synergizes with GVAX. Vaccination and anti-OX40 immunotherapy are mechanistically complementary, particularly in the glioma microenvironment.

Dataset Information

TMIC-29. REPROGRAMMING BONE MARROW OF TUMOR-BEARING HOSTS FOR GLIOMA IMMUNOTHERAPY

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets